Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:UCB
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:focus |
rare diseases
complement-mediated diseases |
| gptkbp:foundedYear |
2008
|
| gptkbp:founder |
Douglas Treco
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ra Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
zilucoplan
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
RARX
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.rapharma.com/
|
| gptkbp:bfsParent |
gptkb:Lightstone_Ventures
|
| gptkbp:bfsLayer |
8
|